#### CORCEPT THERAPEUTICS INC

Form 4 July 14, 2017

FORM 4	OMB APPROVAL									
	OMB Number:	3235-0287								
Check this box if no longer		FMFNT O	F CHANGES IN BENEFICIAL OV	Expires:	January 31, 2005					
subject to Section 16.	SIAI		SECURITIES SECURITIES	Estimated a burden hour	rs per					
Form 4 or Form 5 obligations may continue. See Instruction 1(b).  Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Respo	onses)									
1. Name and Address of Reporting Person * MAHONEY DAVID L			2. Issuer Name <b>and</b> Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]	Issuer						
(Last)  C/O CORCEPT INCORPORATI		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/12/2017	_X Director Officer (give t below)		Owner er (specify				
COMMONWE		IVE								
MENLO PARK	(Street) , CA 9402	25	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joi Applicable Line) _X_ Form filed by O Form filed by M Person	ne Reporting Pe	rson				
(City)	(State)	(Zip)	Table I - Non-Derivative Securities A	equired, Disposed of,	or Beneficial	ly Owned				
1.Title of 2. Tr	ansaction D	ate 2A. Deen	ned 3. 4. Securities Acquired	5. Amount of	6.	7. Nature of				

(City)	(State)	(Zip) Tab	le I - Non-l	Derivative	Secu	rities Acqu	iired, Disposed o	f, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	Held by David L.
Common Stock	07/12/2017		S <u>(1)</u>	6,510	D	\$ 12.5	1,129,163	I	Mahoney and Winnifred C. Ellis 1998 Family
	07/13/2017		S <u>(1)</u>	484	D		1,128,679	I	Trust

#### Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

Common Held by 12.548 Stock David L. (2) Mahoney and

Winnifred C. Ellis 1998 Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

**SEC 1474** (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transact	5. iorNumber	6. Date Exercise Expiration D		7. Title Amou		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	or Exercise Price of Derivative Security	(2.20.11.2.3)	any (Month/Day/Year)	Code (Instr. 8)	of	(Month/Day/ e		Underl Securit	lying	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
MAHONEY DAVID L						
C/O CORCEPT THERAPEUTICS INCORPORATED	X					
149 COMMONWEALTH DRIVE	Λ					
MENLO PARK, CA 94025						

## **Signatures**

/s/ G. Charles Robb, Attorney-in-Fact for David L. 07/14/2017 Mahoney

\*\*Signature of Reporting Person

2 Reporting Owners

Date

#### Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale is made pursuant to terms of 10b5-1 plan in effect at the time of sale of the shares.
- (2) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$12.52 to \$12.56 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.